# A High-Throughput Platform for COVID-19 Serodiagnosis, Vaccine Evaluation, and Drug Discovery

> **NIH NIH R01** · UNIVERSITY OF TEXAS MED BR GALVESTON · 2020 · $699,894

## Abstract

ABSTRACT
In response to the current COVID-19 pandemic, it is of paramount importance to rapidly diagnose
infections and to develop countermeasures. This project aims to build a high-throughput platform
for rapid COVID-19 serodiagnosis, vaccine evaluation, and therapeutics development.

## Key facts

- **NIH application ID:** 10142203
- **Project number:** 3R01AI134907-03S2
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **Principal Investigator:** Ricardo Rajsbaum
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $699,894
- **Award type:** 3
- **Project period:** 2020-05-01 → 2021-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10142203

## Citation

> US National Institutes of Health, RePORTER application 10142203, A High-Throughput Platform for COVID-19 Serodiagnosis, Vaccine Evaluation, and Drug Discovery (3R01AI134907-03S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10142203. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*